TAS2R expression was analyzed in 61 AML, 49 from a published dataset (32 (link)) and 12 new cases. As validation set, we used also 183 AML samples downloaded from The Cancer Genome Atlas (TCGA) (https://gdc.cancer.gov/about-data/publications/laml_2012 ) (33 (link)). GEP after DEN treatment was performed in 5 newly diagnosed AML samples and THP-1 and OCI-AML3 cell lines. Three independent replicates of each condition were hybridized to Human Clariom S Arrays (Thermo Fisher Scientific) according to the manufacturer's recommendations. Data quality control, normalization (signal space transformation robust multiple-array average), and supervised analysis were carried out by Expression Console and Transcriptome Analysis Console software, respectively (Thermo Fisher Scientific). For AML cells, data were normalized on vehicle-treated cells before comparison. Genes with a 1.5 fold difference and p ≤ 0.05 were considered for enrichment analyses. Downstream analyses were performed as reported in (32 (link), 34 (link)), and with Thomson Reuter's MetaCore software suite (Clarivate Analytics, Philadelphia, PA, USA). Gene expression data of denatonium-treated cells will be publicly available on the GEO database under the accession number GSE149548 .
Free full text: Click here
